Get the Stockscreener App
4.61
2.12%
-0.10
After Hours:
4.51
-0.10
-2.17%
Precision Biosciences Inc stock is traded at $4.61, with a volume of 178.14K.
It is down -2.12% in the last 24 hours and down -9.43% over the past month.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
See More
Previous Close:
$4.71
Open:
$4.54
24h Volume:
178.14K
Relative Volume:
0.39
Market Cap:
$48.32M
Revenue:
$52.29M
Net Income/Loss:
$-73.52M
P/E Ratio:
-6.9848
EPS:
-0.66
Net Cash Flow:
$-100.45M
1W Performance:
-1.91%
1M Performance:
-9.43%
6M Performance:
-50.96%
1Y Performance:
-67.85%
1-Day Range:
$4.4796
$4.71
1-Week Range:
$4.25
$4.99
52-Week Range:
$3.61
$14.93
Precision Biosciences Inc Stock (DTIL) Company Profile
Name
Precision Biosciences Inc
Sector
Industry
Phone
919-314-5512
Address
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
4.61 | 48.32M | 52.29M | -73.52M | -100.45M | -0.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-30-24 | Initiated | Guggenheim | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Jun-09-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-27-20 | Resumed | BTIG Research | Buy |
| Apr-03-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-05-20 | Initiated | Stifel | Buy |
| Feb-25-20 | Initiated | William Blair | Outperform |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-16-19 | Initiated | H.C. Wainwright | Buy |
| Apr-22-19 | Initiated | Barclays | Overweight |
| Apr-22-19 | Initiated | Goldman | Buy |
| Apr-22-19 | Initiated | JP Morgan | Overweight |
| Apr-22-19 | Initiated | Jefferies | Buy |
View All
Precision Biosciences Inc Stock (DTIL) Latest News
SEC Form PRE 14A filed by Precision BioSciences Inc. - Quantisnow
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Gene Editing Pioneer Precision BioSciences Reveals Latest ARCUS Platform Progress at Major Healthcare Conference - Stock Titan
Precision Biosciences director Kevin Buehler buys $21,122 in stock - Investing.com Australia
Precision Biosciences director Melinda Brown buys $8,735 in stock By Investing.com - Investing.com South Africa
Precision Biosciences director Melinda Brown buys $8,735 in stock - Investing.com India
Precision Biosciences director Kevin Buehler buys $21,122 in stock By Investing.com - Investing.com Canada
Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates - MSN
Precision Biosciences director Germano Geno J purchases $17,225 in stock By Investing.com - Investing.com South Africa
Precision Biosciences director Germano Geno J purchases $17,225 in stock - Investing.com India
Precision BioSciences: Q4 Earnings Snapshot - Big Rapids Pioneer
Precision BioSciences Reports Positive 2024 Financial Results - TipRanks
Precision BioSciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
PRECISION BIOSCIENCES Earnings Results: $DTIL Reports Quarterly Earnings - Nasdaq
Precision Biosciences Reports Fourth Quarter And FY 2024 Results - MarketScreener
Precision BioSciences Inc Q4 Sales Decline - Nasdaq
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update - Business Wire
Breakthrough: Precision BioSciences' Gene Editing Therapy Delivers First Results in HBV Patients - Stock Titan
Precision Biosciences CEO sells $5,359 in stock By Investing.com - Investing.com Australia
Precision Biosciences CEO sells $5,359 in stock - Investing.com India
Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases - Business Wire
PRECISION BIOSCIENCES Earnings Preview: Recent $DTIL Insider Trading, Hedge Fund Activity, and More - Nasdaq
Gene Editing Tools Market Growth Demand, Segment Analysis - openPR.com
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025 - BioSpace
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025 - Business Wire
Precision BioSciences Earnings Call: Key ARCUS Gene Editing Platform Updates Expected March 26 - StockTitan
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
H.C. Wainwright maintains $60 target on Precision BioSciences stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains $60 target on Precision BioSciences stock - Investing.com
Revolutionary Gene Therapy Achieves 99% Hepatitis B Virus EliminationKey Trial Updates - Stock Titan
Precision Bio rises after gene editing data: BMO upgrades (update) - MSN
Assessing Precision BioSciences: Insights From 4 Financial Analysts - Benzinga
FDA Clears First-Ever In Vivo Gene-Editing Trial for Chronic Hepatitis B in the United States - CRISPR Medicine News
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - 01Net
Revolutionary DMD Treatment Restores 93% Muscle Strength, Could Help 60% of Patients - StockTitan
Precision BioSciences' IND Application For PBGENE-HBV Gets FDA Clearance; Stock Climbs - RTTNews
Precision Says its Investigational New Drug Application for Hepatitis B Treatment Gets US FDA's Clearance - MarketScreener
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - NewsBreak: Local News & Alerts
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B - BioSpace
Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel (NASDAQ:DTIL) - Seeking Alpha
Precision Biosciences Inc Stock (DTIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Precision Biosciences Inc Stock (DTIL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Brown Melinda | Director |
Mar 26 '25 |
Buy |
4.75 |
1,839 |
8,735 |
9,057 |
| Germano Geno J | Director |
Mar 25 '25 |
Buy |
5.30 |
3,250 |
17,225 |
11,057 |
| Amoroso Michael | President and CEO |
Mar 24 '25 |
Sale |
5.56 |
964 |
5,360 |
109,540 |
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):